Table S1. Multivariate analysis final model of patients under 60 year old (n = 174)

Variable	Beta	Standard error	t	Exponent beta	Wald - statistic	P
ARC	-0.317	0.140	-2.273	0.728	5.165	0.02306
Age.at.Dx	0.040	0.011	3.560	1.041	12.670	0.00037
CytoGrp#	-0.861	0.182	-4.731	0.423	22.386	0.00000
FLT3Mutant	0.535	0.247	2.165	1.707	4.687	0.03040
WBC	0.005	0.002	2.689	1.005	7.233	0.00716
Albumin	-0.299	0.129	-2.309	0.742	5.332	0.02095

Figure S1. Martingale residual plot of ARC levels


Martingale residuals from null

Figure S2. ARC expression and clinical outcome of AML patients with intermediate cytogenetics. (A) ARC level and overall survival ($P = 0.014$). (B) ARC level and remission duration ($P = 0.015$).

Figure S3. ARC expression and clinical outcome of AML patients with normal cytogenetics.
(A) ARC level and overall survival ($P = 0.03$). (B) ARC level and overall survival of AML patients with normal cytogenetics and NPM1 mutation ($P = 0.0015$), and (C) ARC level and overall survival of AML patients with normal cytogenetics and wild type NPM1 ($P = 0.36$).

Figure S4. ARC expression and clinical outcome of AML patients with or without NPM1 mutations in all cytogenetic groups. (A) ARC level and overall survival of AML patients with NPM1 mutation (*P* = 0.003). (B) ARC level and overall survival of AML patients with wild type NPM1 (*P* = 0.12).

Figure S5. ARC expression and clinical outcome of adult AML patients under 60 years old with normal karyotype. ARC level and overall survival ($P = 0.010$).

Figure S6. ARC expression and clinical outcome of AML patients treated with antracycline + HDAC (P = 0.04).